| Literature DB >> 26036268 |
Hagop M Kantarjian1, Robert Chapman2.
Abstract
The 340B program, a drug discount program created by the US Congress, allows safety-net providers to access discounted drug pricing that helps low-income and vulnerable patients. This program has recently been the subject of significant discussions as to its potential implications. Herein we review the role of the 340B drug discount program and its relevance to recent trends in cancer care and to the access of safety-net providers and vulnerable patients to much-needed drug support.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26036268 DOI: 10.1200/JOP.2014.002139
Source DB: PubMed Journal: J Oncol Pract ISSN: 1554-7477 Impact factor: 3.840